特应性皮炎(AD)是最常见的慢性炎症性皮肤病,几十年来,AD的治疗仅限于局部皮质类固醇、局部钙调神经磷酸酶抑制剂,对于中重度AD患者,则仅限于光疗和全身免疫抑制剂.随着AD发病机制地深入研究,许多局部和全身靶向治疗药物正在研发中,可能会改变AD的治疗选择.本文结合目前最新的临床试验对AD生物靶向治疗的种类、机制、疗效和安全性研究作一综述,为AD个体化治疗提供一定的理论依据.
Atopic dermatitis(AD)is the most common chronic inflammatory skin disease.For decades,the treatment of AD has been limited to local corticosteroid or calcineurin inhibitors,and light therapy or systemic immunosuppressive drug for moderate to severe AD patients.With the in-depth study of the pathogenesis of AD,many local and systemic targeted therapy drugs are being developed,which may change the treatment options of AD.This review combination with the latest clinical trials give a summarize on the type,mechanism,efficacy and safety of biological targeted therapy for AD,to provide a theoretical basis for the individualized treatment of AD.
刘盈;姚采君;曾晖;陈季芳;周春
广州新华学院药学院,广东广州 510520南方医科大学药学院,广东广州 510515
药学
特应性皮炎;生物制剂;靶向治疗;临床试验
atopic dermatitis;biological agents;targeted therapy;clinical trial
《中国临床药理学杂志》 2024 (005)
768-772 / 5
广州市科技计划基础与应用基础基金资助项目(202201011806);广东省教育厅科研基金资助项目(2017KTSCX213)
10.13699/j.cnki.1001-6821.2024.05.029
评论